Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 4
2018 3
2019 2
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Univariate and Multivariate Determination of Dapagliflozin and Saxagliptin in Bulk and Dosage Form.
Elhassan MM, Mahmoud AM, Hegazy MA, Mowaka S. Elhassan MM, et al. J AOAC Int. 2023 May 3;106(3):794-803. doi: 10.1093/jaoacint/qsac143. J AOAC Int. 2023. PMID: 36355446
OBJECTIVE: The aim of this work is to develop four simple, accurate, and precise UV-spectrophotometric methods, three univariate and one multivariate, for the estimation of dapagliflozin and saxagliptin in their pure and marketed dosage forms. ...CONCLUSION: …
OBJECTIVE: The aim of this work is to develop four simple, accurate, and precise UV-spectrophotometric methods, three univariate and one mul …
Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial.
Koshino A, Neuen BL, Jongs N, Pollock C, Greasley PJ, Andersson EM, Hammarstedt A, Karlsson C, Langkilde AM, Wada T, Heerspink HJL. Koshino A, et al. Cardiovasc Diabetol. 2023 Nov 28;22(1):330. doi: 10.1186/s12933-023-02027-8. Cardiovasc Diabetol. 2023. PMID: 38017482 Free PMC article. Clinical Trial.
METHODS: Patients with type 2 diabetes and albuminuria were randomized to dapagliflozin, dapagliflozin and saxagliptin, or placebo. We measured hemoglobin, iron markers (serum iron, transferrin saturation, and ferritin), plasma erythropoietin, and inflammator …
METHODS: Patients with type 2 diabetes and albuminuria were randomized to dapagliflozin, dapagliflozin and saxagliptin, …
Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
Pollock C, Stefánsson B, Reyner D, Rossing P, Sjöström CD, Wheeler DC, Langkilde AM, Heerspink HJL. Pollock C, et al. Lancet Diabetes Endocrinol. 2019 Jun;7(6):429-441. doi: 10.1016/S2213-8587(19)30086-5. Epub 2019 Apr 13. Lancet Diabetes Endocrinol. 2019. PMID: 30992195 Clinical Trial.
Sequential Treatment Escalation with Dapagliflozin and Saxagliptin Improves Beta Cell Function in Type 2 Diabetic Patients on Previous Metformin Treatment: An Exploratory Mechanistic Study.
Forst T, Alghdban MK, Fischer A, Weber MM, Voswinkel S, Heise T, Kapitza C, Plum-Mörschel L. Forst T, et al. Horm Metab Res. 2018 May;50(5):403-407. doi: 10.1055/a-0591-9442. Epub 2018 May 4. Horm Metab Res. 2018. PMID: 29727906 Clinical Trial.
We investigated the effect of sequential treatment escalation with dapagliflozin and saxagliptin on beta cell function in patients with T2DM insufficiently controlled on metformin monotherapy during a hyperglycaemic clamp investigation. ...After the addition …
We investigated the effect of sequential treatment escalation with dapagliflozin and saxagliptin on beta cell function …
COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION.
Ekholm E, Hansen L, Johnsson E, Iqbal N, Carlsson B, Chen H, Hirshberg B. Ekholm E, et al. Endocr Pract. 2017 Mar;23(3):258-265. doi: 10.4158/EP161323.OR. Epub 2016 Nov 16. Endocr Pract. 2017. PMID: 27849380 Clinical Trial.
RESULTS: At 24 weeks, compared with baseline, saxagliptin + dapagliflozin and saxagliptin + placebo increased mean (95% confidence interval [CI]) C-peptide area under the curve (AUC(0-180 min)) (40.2 [9.2 to 71.3] ng/mL and 95.4 [63.4 to 127.4] ng/mL, respect …
RESULTS: At 24 weeks, compared with baseline, saxagliptin + dapagliflozin and saxagliptin + placebo increased mean (95% …
Novel univariate spectrophotometric determination of the recently released solid dosage form comprising dapagliflozin and saxagliptin via factorized response spectra: Assessment of the average content and dosage unit uniformity of tablets.
Lotfy HM, Mohamed D, Elshahed MS. Lotfy HM, et al. Spectrochim Acta A Mol Biomol Spectrosc. 2019 Nov 5;222:117120. doi: 10.1016/j.saa.2019.05.025. Epub 2019 May 16. Spectrochim Acta A Mol Biomol Spectrosc. 2019. PMID: 31252262
Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin.
Del Prato S, Rosenstock J, Garcia-Sanchez R, Iqbal N, Hansen L, Johnsson E, Chen H, Mathieu C. Del Prato S, et al. Diabetes Obes Metab. 2018 Jun;20(6):1542-1546. doi: 10.1111/dom.13258. Epub 2018 Mar 25. Diabetes Obes Metab. 2018. PMID: 29446523 Free PMC article. Clinical Trial.
The safety of triple oral therapy with dapagliflozin plus saxagliptin plus metformin versus dual therapy with dapagliflozin or saxagliptin plus metformin was compared in a post-hoc analysis of 3 randomized trials of sequential or concomitant add-on of dapagliflozin and …
The safety of triple oral therapy with dapagliflozin plus saxagliptin plus metformin versus dual therapy with dapagliflozin or saxagliptin p …
SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus.
Dey J. Dey J. Postgrad Med. 2017 May;129(4):409-420. doi: 10.1080/00325481.2017.1307081. Epub 2017 Apr 3. Postgrad Med. 2017. PMID: 28322073 Review.
This article reviews the rationale for combination therapy with these agents, and evidence from clinical trials with empagliflozin and linagliptin or dapagliflozin and saxagliptin in the management of type 2 diabetes mellitus. ...
This article reviews the rationale for combination therapy with these agents, and evidence from clinical trials with empagliflozin and linag …
13 results